LOS ANGELES, May 7 (Reuters) - A panel of expert advisers to the U.S. Food and Drug Administration will meet at the end of this month to review GlaxoSmithKline Plc's experimental drug for treating a disorder in which the blood does not clot properly, according to Amgen Inc.
